Cantabio Pharmaceuticals IncOver The Counter Market:CTBO
- LAST PRICE1.0100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 1.0100
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cantabio Pharmaceuticals Inc | 22.8K | 0.0x | --- |
Pathfinder Cell Therapy Inc | 670.0 | 0.0x | --- |
IR BioSciences Holdings Inc | 20.0 | 0.0x | --- |
Sienna Biopharmaceuticals Inc | 30.0 | 0.0x | --- |
VIA Pharmaceuticals Inc | 20.0 | 0.0x | --- |
Vaxxinity Inc | 25.4K | 0.0x | --- |
Company Information
Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company. The Company is focused on commercializing therapies and the intellectual property generated from its research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases. The Company’s small molecule therapy candidates program (CB101) and protein therapy candidate (CB201) targets Parkinson’s disease and a range of neurodegenerative diseases including Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease and stroke. It also has two additional small molecule pharmacological chaperone programs for the treatment of Alzheimer’s Disease (and other related dementias); CB301, targeting the Tau protein, for the development of Alzheimer’s therapeutics, and CB401, targeting the Aß peptide in Alzheimer’s drug research. The Company’s strategy integrates therapeutic focus on targeting family biophysics and drug discovery technology.
Contact Information
- Headquarters
- 2225 East Bayshore Road, Suite 200PALO ALTO, CA, United States 94303
- Phone
- 302-645-7400
- Fax
- 302-636-5454
Executives
- Chief Executive Officer
- Gergely Toth
- Chief Operating Officer
- Thomas Sawyer
- Director
- Max Zhu
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $22.8K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 22.6K |
Cantabio Pharmaceuticals Inc does not pay a dividend. | |
Beta | --- |
EPS | $-177.35 |
Book Value | $-180.46 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
